Drug Channels

JANUARY 4, 2023

Time for the Drug Channels annual reality check on drug pricing. The data once again tell a different story than you might read in your favorite politician’s Twitter feed or misleading news reports. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year.

Branding 94

Branding Drugs 94

Drug Channels

JUNE 27, 2023

Before you launch your July 4 festivities, Drug Channels offers some fireworks of our own: My $0.02 on the Humira price war—and the role of cost-plus pharmacy pricing Fresh evidence that formulary exclusions hurt patients Disturbing oncology drug benefit management Plus, an entertaining explanation of why the U.S.

Drugs 79

Drugs Pharmacy 79

World of DTC Marketing

SEPTEMBER 23, 2021

The suggestion by Pfizer’s CEO that drug pricing negotiations with the government would slow innovation is PR doubletalk. Yesterday STAT news reported that because of the slow uptake of their Alzheimer’s drug, they might be forced to change business plans which include layoffs.

Vaccination 214

Vaccination Vaccine Drugs Packaging 214

Drug Channels

MARCH 31, 2023

Time for the Drug Channels annual reality check on drug pricing. The data once again tell a different story than you might read in your favorite politician’s Twitter feed or misleading news reports. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year.

Branding 73

Branding Drugs Pharmacy 73

World of DTC Marketing

JANUARY 24, 2022

Venture capitalists have poured $42 billion into drug development over the past three years. Most small biotech companies rely on venture capitalist funding to develop new drugs but is that a good way to go? billion, which was much lower than previous studies, which have placed the average cost of drug development as $2.8

Life Science 225

Life Science Drugs Genetic Disease Development 225

Pharmaceutical Technology

DECEMBER 27, 2022

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Tracking the news. Tracking drug development. Alzheimer’s disease drugs were constantly in the news, and not always for the right reasons.

Clinical Trials 306

Clinical Trials Clinical Trials Trials Vaccination 306

Drug Channels

SEPTEMBER 27, 2023

d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. I recommend that you follow me on LinkedIn, because the quality of comments and engagement is much higher than they are on Twitter. I’m not posting to Threads yet.) Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmacy 74

Pharmacy Generic Drugs Drugs 74

Drug Channels

NOVEMBER 28, 2023

In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference! d/b/a Drug Channels Institute.

Pharmacy 74

Pharmacy Drugs Cardiology Marketing 74

World of DTC Marketing

NOVEMBER 10, 2020

SUMMARY : Pfizer’s 90 percent effectiveness is very impressive, but the rate is based on a relatively small number of people and the data has not been peer-reviewed but today headlines rule the news, not content. Pfizer’s results are promising and are coming at a time when the world is anxiously awaiting positive news.

Vaccination 286

Vaccination Vaccine Marketing Drugs 286

Drug Channels

DECEMBER 15, 2023

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. I couldn’t wait to share the news, hence this special Sunday post. d/b/a Drug Channels Institute.

Pharmacy 79

Pharmacy Manufacturing Drugs 79

STAT News

AUGUST 11, 2022

And what will Medicare negotiation mean for drug prices? We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry. Read the rest…

Gene Therapy 98

Gene Therapy Life Science Drugs Scientist 98

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma Companies 210

Pharma Companies Marketing Drugs Production 210

World of DTC Marketing

FEBRUARY 1, 2022

According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. Meanwhile, the Food and Drug Administration has delayed several drug approvals, and Sen.

Drugs 234

Drugs Development Marketing Vaccination 234

Drug Channels

SEPTEMBER 24, 2023

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. I couldn’t wait to share the news, hence this special Sunday post. The difference between list prices and discounted 340B purchases also grew, to $52.3 d/b/a Drug Channels Institute. billion —an astonishing $9.8

Pharmacy 69

Pharmacy Manufacturing Drugs 69

STAT News

MARCH 3, 2023

… Now that Eli Lilly slashed the price for some of its insulin products, the moves raised questions about what will happen to other efforts to provide low-cost insulin, Kaiser Health News explains. And the Mark Cuban Cost Plus Drug Co. But drug=pricing experts predict Lilly’s moves will not undercut those efforts.

Insulin 98

Insulin Drugs Production Marketing 98

NPR Health - Shots

MARCH 18, 2023

More drug companies lowered list prices for insulin this week. NPR's Scott Simon speaks with Kaiser Health News reporter Bram Sable-Smith about what that means for patients.

Insulin 57

Insulin Drugs 57

pharmaphorum

OCTOBER 3, 2022

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 per year in the US, sparking outcry. ALS affects over 30,000 people in the US.

Drugs 52

Drugs Generic Drugs FDA Approval Trials 52

STAT News

MARCH 2, 2023

What happens when a drug company actually lowers prices? We also discuss the latest news in the life sciences, including Eli Lilly slashing the cost of insulin, succession at the FDA, and how pandemic boom times have turned to bust. Who invented CRISPR 2.0? And is Novavax going to survive? Read the rest…

Insulin 98

Insulin Life Science Drugs 98

World of DTC Marketing

FEBRUARY 2, 2022

Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. Food and Drug Administration on Biogen Inc.’s Food and Drug Administration on Biogen Inc.’s

FDA Approval 239

FDA Approval Drugs Doctors Doctor 239

Camargo

NOVEMBER 15, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. It created the possibility of more easily obtaining information to support new product indications or to help with post-approval study requirements.

Development 187

Development Manufacturing Production Packaging 187

STAT News

OCTOBER 27, 2022

We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams. Read the rest…

Life Science 98

Life Science Vaccination Vaccine Drugs 98

Pharmaceutical Technology

OCTOBER 13, 2022

The news of the offer came just weeks after Myovant and its partner, Pfizer , received the US Food and Drug Administration's (FDA) expanded approval of Myfembree (estradiol + norethindrone acetate + relugolix) for the management of moderate to severe pain associated with endometriosis. to a share in cash.

Hormones 130

Hormones FDA Approval Drugs Marketing 130

The Pharma Data

JANUARY 6, 2021

6, 2021 — With the new year comes another round of prescription drug price hikes, CBS News reported Tuesday. The data come from 46brooklyn Research, a nonprofit company that aims to improve access to drug pricing information. In all, more than 500 drugs will cost more this year. WEDNESDAY, Jan.

Drugs 52

Drugs Branding Medicine Production 52

XTalks

MARCH 15, 2024

LillyDirect Pharmacy Solutions, Eli Lilly’s direct-to-consumer (DTC) drugs website, is teaming up with Amazon Pharmacy to deliver select medications to people’s homes. The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab).

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

Drug Channels

SEPTEMBER 28, 2021

Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Drugs 55

Drugs Pharmacy Trials 55

World of DTC Marketing

JULY 13, 2021

SUMMARY: The FDA has many puzzled as to why they approve some drugs with questionable data and ask for more data on other drugs. The FDA approves drugs on the potential to save a life, the cost of the drugs is never considered in the process. Our healthcare system cannot continue to support marginally effective drugs.

Drugs 187

Drugs FDA Approval Medicine Trials 187

Drug Channels

JULY 27, 2021

In this issue: The top 10 stingiest hospitals Medicare Part B's savings from biosimilars What happened to hepatitis C drug costs and rebates? d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Costco beats Medicare Part D Plus, math madness with Duke’s Fuqua business school.

Drugs 52

Drugs 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

Amarin is going full steam ahead with its plans for global expansion of its cardiovascular drug Vazkepa (Vascepa/icosapent ethyl). Last week, at the HC Wainwright Investment Conference, Amarin’s CEO, Karim Mikhail, spoke of the company’s plans to widen the scope of the drug. Vazkepa is Amarin’s only marketed drug.

FDA Approval 130

FDA Approval Marketing Drugs Production 130

STAT News

OCTOBER 6, 2022

… Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” according to Stuart Arbuckle, chief operating officer at Vertex Pharmaceuticals, which is preparing to market its own treatment for sickle-cell disease , Bloomberg News tells us. Even

Gene Therapy 98

Gene Therapy Gene Insulin Drugs 98

Drug Channels

SEPTEMBER 30, 2020

We’ve been squirrelling away these acorns from the mighty Drug Channels oaks: I agree. Brand-name drugs prices keep on dropping It’s official: CVS Health’s Zinc GPO actually exists! d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Autumn is here!

Drugs 52

Drugs Branding 52

World of DTC Marketing

MARCH 1, 2022

The lack of choice limits competition, which can drive prices higher. That rise is almost entirely due to higher prices because enrollment and demand for services among the commercially insured have barely budged, or fallen. With inflation in the news, healthcare costs are continuing to rise. Half of U.S.

Drugs 154

Drugs Medicine 154

Pharmaceutical Technology

SEPTEMBER 26, 2022

The 'life-extending' drug combination is recommended for usage in adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who have previously received hormone therapy. An inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), palbociclib is administered once a day as a pill.

HR 130

HR Drugs Hormones Medicine 130

World of DTC Marketing

JUNE 30, 2021

SUMMARY: The pharmaceutical trade publications, except STAT News and Endpoints, have remained silent on the sham approval of Biogen’s Alzheimer’s drug. The total disaster that has become the FDA has been covered well by only two publications: STAT News and Endpoints. It’s disgusting. I’m sorry.

Drugs 155

Drugs Development Research 155

World of DTC Marketing

FEBRUARY 7, 2022

According to Endpoint News” We’ve seen Biogen’s CSO exit under pressure in recent weeks, and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial approval of Aduhelm for Alzheimer’s. At 99% of pharma companies, that’s a huge no-no.

Pharma Companies 253

Pharma Companies Marketing Sales Clinical Trials 253

XTalks

MAY 25, 2021

AbbVie (NYSE:ABBV) continues to face heat over complaints of patent exploitation and price hikes of its world’s best-selling drug Humira (adalimumab) to build a market monopoly and block out Humira biosimilar competition. A recent congressional probe provided confirmation of the claims. Biosimilars.

Production 98

Production Drugs Marketing Sales 98

World of DTC Marketing

JULY 28, 2020

It has issued a stream of news releases hailing its vaccine progress, and its stock has more than tripled, giving the company a market value of almost $30 billion. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19” “Vaxart’s shares soared.

Vaccination 181

Vaccination Vaccine Pharma Companies Development 181

World of DTC Marketing

JUNE 23, 2021

Source: Fierce Pharma If that enthusiasm pans out in the long run, it could mean at least 300,000 patients taking the drug, or $10 billion to $15 billion in peak Aduhelm from U.S. One agency FDA adviser, resigning from his committee post in protest, called it “probably the worst drug approval decision in recent U.S. government.

Drugs 218

Drugs FDA Approval Doctors Doctor 218